Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer - PubMed (original) (raw)
. 2012 Apr 15;72(8):1935-42.
doi: 10.1158/0008-5472.CAN-11-3266. Epub 2012 Feb 24.
Sharon J Pitteri, Christopher I Li, Martin McIntosh, Jon J Ladd, Mary Disis, Peggy Porter, Chee Hong Wong, Qing Zhang, Paul Lampe, Ross L Prentice, Samir M Hanash
Affiliations
- PMID: 22367215
- PMCID: PMC4066614
- DOI: 10.1158/0008-5472.CAN-11-3266
Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer
Lynn M Amon et al. Cancer Res. 2012.
Abstract
Although the identification of peripheral blood biomarkers would enhance early detection strategies for breast cancer, the discovery of protein markers has been challenging. In this study, we sought to identify coordinated changes in plasma proteins associated with breast cancer based on large-scale quantitative mass spectrometry. We analyzed plasma samples collected up to 74 weeks before diagnosis from 420 estrogen receptor (ER)(+) cases and matched controls enrolled in the Women's Health Initiative cohort. A gene set enrichment analysis was applied to 467 quantified proteins, linking their corresponding genes to particular biologic pathways. On the basis of differences in the concentration of individual proteins, glycolysis pathway proteins exhibited a statistically significant difference between cases and controls. In particular, the enrichment was observed among cases in which blood was drawn closer to diagnosis (effect size for the 0-38 weeks prediagnostic group, 1.91; P, 8.3E-05). Analysis of plasmas collected at the time of diagnosis from an independent set of cases and controls confirmed upregulated levels of glycolysis proteins among cases relative to controls. Together, our findings indicate that the concomitant release of glycolysis proteins into the plasma is a pathophysiologic event that precedes a diagnosis of ER(+) breast cancer.
Figures
Figure 1. Quantified proteins in the glycolytic pathways
Color representation consists of red (increased levels), green (decreased levels) and yellow (no significant quantitative change) based on log2 ratios for the 0–38 week pre-diagnostic samples relative to matched controls.
Figure 2. Extensive peptide coverage for glycolysis proteins
Representative data for the identification of three glycolysis proteins, ALDOA, ENO1 and GAPDH, in a case control experiment illustrate the extent of coverage achieved in the identification of glycolysis proteins in plasma by mass spectrometry in this study. For each protein, the peptides identified are displayed below the predicted tryptic peptides. Orange indicates cysteine containing peptides used for determination of case/control ratios.
Figure 3. Gene set enrichment analysis in relation to time to diagnosis
The x-axis represents the rank of each protein's log2 ratio in descending order while the y-axis is the proportion of proteins represented in the gene set for each rank as utilized for gene set enrichment scores (6) which are normalized such that cumulative score is zero. The area under the curve (AUC) serves as a measure of how the protein ratios in one gene set are distributed among all proteins measured.
References
- Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149–54. - PubMed
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. - PubMed
- Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61–109. - PubMed
- Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452:571–9. - PubMed
- Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA015704/CA/NCI NIH HHS/United States
- 1 R21 161713-01/PHS HHS/United States
- R21 CA161713/CA/NCI NIH HHS/United States
- N01 WH074313/WH/WHI NIH HHS/United States
- U01 CA141550/CA/NCI NIH HHS/United States
- U01 CA111273/CA/NCI NIH HHS/United States
- UO1 CA111273/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical